Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783525 | 0.98 | HDAC4 (0.51) | KMOHDAC4HDAC2HDAC8ENPP2 | |
| SCHEMBL3786808 | 0.94 | HDAC4 (0.47) | KMOHDAC4HDAC2HDAC8ENPP2 | |
| SCHEMBL3784993 | 0.90 | ENPP2 (0.48) | KMOHDAC4HDAC2HDAC8ENPP2 | |
| SCHEMBL32669062 | 0.84 | ENPP2 (0.42) | KMOHDAC4HDAC2HDAC8ENPP2 | |
| SCHEMBL3789096 | 0.82 | KMO (0.39) | KMOHDAC4HDAC2HDAC8KDM4E | |
| Hydrogen Peroxide SCHEMBL11391460 | 0.82 | KMO (0.71) | KMOHDAC4HDAC2HDAC8KDM4E | |
| SCHEMBL5667650 | 0.82 | KMO (0.64) | KMOHDAC4HDAC2HDAC8CYP11B2 | |
| SCHEMBL669730 | 0.82 | KMO (0.64) | KMOHDAC4HDAC2HDAC8CYP11B2 | |
| SCHEMBL3790896 | 0.80 | HDAC8 (0.37) | KMOHDAC4HDAC2HDAC8KDM4E | |
| SCHEMBL5666805 | 0.80 | KMO (0.62) | KMOHDAC4HDAC2HDAC8CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | KMO 19/4885HDAC4 3220/4885HDAC2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.